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ABSTRACT
METABOLOMICS OF TRANSFORMED MDA-MB-231 CELL LINES EXPRESSING DIFFERENT
LEVELS OF HUMAN ARYLAMINE N-ACETYLTRANSFERASE 1 (NAT1)
Samantha Marie Carlisle
July 9, 2015
Human arylamine N-acetyltransferase 1 (NAT1) is a phase II xenobiotic metabolizing
enzyme that is found in almost all tissues of the body. Expression of NAT1 is commonly elevated
in several cancers including breast cancer. However, the exact mechanism by which NAT1
expression affects cancer risk and progression remains unclear. Three MDA-MB-231 breast
adenocarcinoma cell lines that stably express wild-type, increased, and decreased levels of
human NAT1 have been constructed and characterized for NAT1 mRNA, NAT1 acetylation
activity, cell doubling rates, and endogenous acetyl-CoA levels. Differences in polar metabolic
profile between these three cell lines were investigated using a comprehensive GC×GC−TOF MS
system. Increased levels of human NAT1 in the transformed cell lines resulted in a statistically
significant decreased abundance of the metabolite palmitoleic acid with one-way ANOVA p =
0.0004, when compared to normal and decreased levels of human NAT1. We hypothesize that
increased NAT1 activity leads to increased hydrolysis of acetyl-CoA thus leaving less acetyl-CoA
available to participate in other reactions. The fatty acid synthesis pathway utilizes acetyl-CoA in
the first two reactions of the pathway and eventually leads to the synthesis of palmitoleic acid
(16:1). These data suggest a link between increased levels of NAT1 activity and decreased flux of
acetyl-CoA through this portion of the fatty acid synthesis pathway.
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INTRODUCTION

It is estimated that in 2015 breast cancer will account for 29% of all new cancer cases
diagnosed in women and 15% of all cancer related deaths in women [1]. From 2002-2003 there
was a sharp decline in breast cancer incidence in non-Hispanic Caucasian women correlating
with the decreased use of hormone replacement therapy, but that trend did not continue into the
subsequent years [2]. From 2004 to 2010, breast cancer incidence rates have not significantly
changed, thus emphasizing the necessity of further investigation into what factors are affecting
breast cancer risk and progression. As more is known about breast cancer, preventative and
treatment options can be improved.
Current breast cancer treatment options include surgery, sentinel lymph node biopsy
followed by surgery, radiation therapy, hormone therapy, targeted therapy, and chemotherapy [3].
Also, for people with a history of familial breast cancer, genetic screenings for mutations in the
tumor suppressor genes BRCA1 and BRCA2 serve as a way to identify breast cancer risk.
Potential onset of the disease can be prevented if mastectomies are performed on those who test
positive for mutations in those genes. Although there are many treatment options for breast
cancer, all come with complicated physical and emotional side effects that decrease the quality of
life of patients. Unfortunately, these treatment and preventative options are not always 100%
effective at eliminating all the cancerous cells, leaving the risk of relapse in addition to the harmful
side effects. Also some cancers, during the course of treatment, become resistant to radiation
therapy, hormone therapy, targeted therapy, and chemotherapy meaning additional measures
must be taken. Due to the harmful side effects, restricted effectiveness, and risk for relapse
associated with current therapies it is important that new treatment options and targets are
explored and elucidated.
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Early detection of breast cancer is extremely important. When breast cancer is detected
in the localized stage, the five-year relative survival rate is an incredible 99%, but when detected
in the distant stage, the five-year relative survival rate is a disappointing 24% [1]. In the earliest
stages of breast cancer, the cancerous cells are localized at the point of origin and can be
removed by surgery with no further intervention required. As breast cancer progresses, more
mutations are incurred and this frequently leads to the breast cancer becoming more aggressive,
invasive, and harder to treat. Once breast cancer has undergone metastasis, harsher and more
aggressive treatments are required. A better understanding of what influences disease risk and
drives disease progression is needed to increase detection of breast cancer in the earliest stage
when it is the most treatable.
Breast cancer is a heterogeneous disease that can be subclassified according to multiple
classifiers including pathology, tumor grade and stage, gene and protein expression, and
immunohistochemical characteristics. One of the most commonly used methods to classify breast
cancer is immunohistochemically according to estrogen receptor (ER), progesterone receptor
(PR), and HER2/neu status. Using this classification system, a triple negative breast cancer
would not express any of these receptors while a triple positive breast cancer would express all
three receptors. Recently, classification based on gene and protein expression has become of
more interest because it may provide clues about what treatment options will be the most
effective for each specific cancer case. Sorlie et al. conducted a study in which gene expression
data of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four
normal breast tissues were evaluated [4]. Based on analysis by hierarchical clustering, six
subtypes were defined. These breast cancer subtypes are 1. Luminal Subtype A, 2. Luminal
Subtype B, 3. Luminal Subtype C, 4. Basal-like, 5. ERBB2+, and 6. Normal Breast-like; these
subtypes are associated with different clinical outcomes in addition to the differences in gene and
protein expression. Other studies have since been conducted looking at the prevalence of each of
these subtypes and have investigated further differences between them [5].
Human arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) are cytosolic phase II
xenobiotic metabolizing isozymes that acetylate a wide range of aromatic and heterocyclic

	
  

2

amines via a ping-pong bi-bi reaction mechanism [6],[7]. NAT1 and NAT2 genes are both located
on chromosome 8p22 [8]. Although NAT1 and NAT2 share approximately 87% coding sequence
homology [9] functional studies have demonstrated significant differences between the two
isozymes in terms of substrate specificity and tissue localization. NAT1 shows substrate
specificity for p-aminosalicylate and p-aminobenzoic acid (PABA) while NAT2 shows substrate
specificity for isoniazid, sulfamethazine, and procainamide [10]. These distinct but overlapping
substrate specificities have been shown to be due to differences in the substrate binding site of
the enzymes [11]. NAT1 and NAT2 also vary in terms of tissue expression with NAT1 being
expressed in most body tissues but NAT2 expression is limited primarily to the liver and GI tract
tissues. Although NAT1 has been shown to be expressed in most body tissues, the only known
endogenous substrate of NAT1, to date, is p-aminobenzoyl-glutamate (PABA-glu), a folate
catabolite [12]. We suspect NAT1 has other endogenous substrates that have yet to be
elucidated, given the extensive tissue distribution and presence in almost all species.
Humans are frequently exposed to NAT substrates. Many therapeutic drugs, including
arylamine drugs such as procainamide, dapsone, and aminoglutethimide, hydrazine drugs such
as isoniazid, hydralazine and phenelzine, and secondary arylamine and hydrazine metabolites
such as sulfasalazine, clonazepam, acebutolol, and caffeine are metabolized by NAT [13].
Aromatic amines, another class of NAT substrates, are found as the byproducts of the
manufacturing of compounds such as polyurethane foams, dyes, pesticides, pharmaceuticals,
and semi-conductors [14]. Aromatic amines are also found in environmental pollution such as
diesel exhaust, combustion of wood chips and rubber, tobacco smoke and well-done grilled
meats [15]. Several of these NAT substrates are environmental carcinogens and their acetylation
leads to either deactivation or bioactivation. One of the most well known and studied NAT
substrates is 4-aminobiphenyl (ABP), a carcinogenic aromatic amine that is a major constituent of
cigarette smoke [16]. The NAT’s play a major role in the deactivation and bioactivation of
carcinogenic aromatic amines and arylamines. Carcinogenic NAT substrates, such as ABP, can
either be N-acetylated (usually deactivation) by NAT, or if first acted upon by a cytochrome P450
enzyme, they can be O-acetylated (usually bioactivation) by NAT. Once bioactivated, these
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compounds can spontaneously form arylnitrenium ions leading to DNA adducts. If not repaired by
nucleotide excision repair (NER), these DNA adducts can lead to mutagenesis and possible
cancer initiation.
Recently it has been shown that human NAT1 can also catalyze the direct hydrolysis of
acetyl-CoA in the absence of a NAT1 arylamine substrate using folate as a cofactor [17]. In this
reaction, the folate is not acetylated, instead the acetate released forms acetyl-CoA is excreted
into the surrounding bulk solvent. Interestingly, the same reaction was not detected in the
presence of human NAT2 instead of human NAT1. The discovery of this additional function of
NAT1 provides support for the hypothesis that NAT1 has an undetermined endogenous role in
addition to the role NAT1 serves as a phase II xenobiotic metabolizing enzyme.
Historically, NAT2 has been of more interest because of the role single nucleotide
polymorphisms (SNPs) in NAT2 play in the metabolism of isoniazid, an anti-tuberculosis drug.
Decreased NAT2 activity due to the presence of SNP’s in “slow” acetylators increases the risk of
developing hepatotoxicity during treatment because isoniazid is eliminated slower when
compared to “rapid” acetylators and accumulates in the liver [18-20]. NAT1 has recently become
of more interest because of the possible link between NAT1 expression and cancer risk and
progression. Examination of publicly available microarray data by others, has shown that changes
in the levels of NAT1 mRNA are associated with specific cancers and cancer subtypes [21]. Of all
cancers, the association between NAT1 and breast cancer has been the most extensively
investigated. A microarray study of 66 breast cancer samples in 2009 by Casey et al., revealed
NAT1 expression was higher in invasive carcinoma compared with normal tissue [21, 22]. Also,
Yuan et al. showed that NAT1 is commonly amplified in breast carcinomas using computational
approaches and a previously published microarray dataset containing 89 breast cancer samples
[23, 24]. Adam et al. have shown by comparative proteomic analysis of 8 normal breast samples
and 25 breast cancer derived tissues that NAT1 is elevated in invasive ductal carcinoma (IDC)
and invasive lobular carcinoma (ILC) when compared to the normal tissue [25]. In the same study
it was also shown that overexpression of NAT1 in HB4a, conditionally immortalized human
mammary luminal epithelial derived cells, enhanced cell growth and resistance to etoposide, a
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cytotoxic anticancer drug, relative to control cells [25]. Smid et al showed in a study of 107 breast
cancer samples that high NAT1 levels in primary tumors were significantly associated with
increased metastasis to the bone [26].
Initially, NAT1 was thought to be monomorphic in terms of acetylation activity but
additional studies have since revealed NAT1 is subject to separate polymorphisms from NAT2
[27-29]. NAT1 contains SNP’s located in the protein region and in the 3’-untranslated regions of
the gene that affect the level of enzymatic activity. Although SNP’s in NAT1 are less common
than those found in NAT2 they still confer distinct differences in NAT1 activity in the human
population. To date, there have been 28 NAT1 alleles identified. Due to the infrequency at which
they occur, roughly half of the NAT1 alleles have yet to be phenotypically defined as conferring
normal, elevated, or decreased NAT1 activity. Data regarding human NAT1 alleles have been
collected and presented at http://nat.mbg.duth.gr/Human%20NAT1%20alleles_2013.htm [30].
The NAT1*4 allele is defined as the reference allele. NAT1*14A, NAT1*14B, NAT1*17, and
NAT1*22 have all been defined as having activity lower than NAT1*4. NAT1*15, NAT1*19A, and
NAT1*19B have been defined as coding for a truncated protein that has no activity. NAT1*20,
NAT1*21, NAT1*23, NAT1*24, NAT1*25, and NAT1*27 have all been defined as having activity
equivalent to the reference allele, NAT1*4. There have been conflicting reports about the activity
of the NAT1*10 allele, some report increased NAT1 activity when compared to the reference
allele but others have seen no difference [31-33]. Interestingly, in a study by Wakefield et al. that
reported the NAT1 activity and genotypes of multiple breast cancer cell lines, the cell lines ZR-751 and MDA-MB-231 had the same NAT1 genotype (NAT1*4/NAT1*4) but varied in activity by
greater than 1,000 fold [34]. In the ZR-75-1 cell line, elevated levels of NAT1 were not due to
alterations in gene copy number. Further analysis has indicated that the NAT1 transcripts in the
ZR-75-1 cell line are produced from the distal promoter NATa while the NAT1 transcripts
produced in all the other cell lines tested were derived from the NATb promoter [35]. There have
also been conflicting data regarding the extent to which these polymorphisms in NAT1 modify risk
of developing breast, colorectal, urinary bladder, head and neck, lung, and prostate cancers.
Adding to the confusion, NAT1 activity is also modulated by a plethora of post-translational and
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environmental factors, including direct chemical modification of the active-site cysteine by
reactive chemical species [36, 37], factors that induce oxidative stress and alter GSH levels [21],
cytokines [38], and through inhibition by small molecule inhibitors [39-41], heavy metals [42],
plant extracts [37], nanoparticles [43], and therapeutic agents [44]. The NAT1 gene copy number
can also be increased or decreased when compared to the standard of two, thus causing
differences in NAT1 activity.
Several studies have demonstrated that expression of NAT1 is significantly linked to
estrogen receptor status in breast cancer samples [45-47]. An evaluation of previously published
microarray data that compared gene expression between ER-positive and ER-negative tissues by
Wakefield et al. showed that NAT1 is in the top three most overexpressed genes in ER-positive
tissue in over 50% of the studies [34]. ER-positive breast cancer can further be subclassified as
luminal A (classically defined as ER
Ki67

high

high

Ki67

low

) and luminal B (classically defined as ER

low

). In a recent study investigating differences in the luminal A and luminal B subtypes of

ER-positive breast cancer published by Endo et al., it was shown that the microRNA (miRNA),
miR-1290 is downregulated in luminal A tumors when compared to luminal B tumors [48]. The
same group has shown in a later publication that miR-1290 binds to a site in the NAT1 3’-UTR
and NAT1 is directly downregulated in a dose-dependent manner by miR-1290 [49]. These data
suggests that downregulation of miR-1290 in luminal A breast cancer leads to overexpression of
NAT1. Interestingly, overexpression of NAT1 in ER-positive breast cancer has been shown to be
correlated with a decreased 5-year relapse rate [50] and NAT1 expression has been shown to be
negatively correlated with tumor size [48].
There have been multiple studies investigating the effects the inhibition of NAT1 has on
immortalized cancer cells. In one study by Tiang et al., in which NAT1 activity in HT-29 cells,
immortalized human colorectal adenocarcinoma cells, was decreased through the use of shRNA,
significant changes in cell growth and morphology were observed when cells were at high density
as opposed to sub-confluent density [51]. In the same study it was also shown that NAT1
knockdown led to increased E-cadherin protein expression and impeded anchorage-independent
growth [51]. Studies have also been conducted in which NAT1 was inhibited by small molecules.
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In one such study Rhod-o-hp, a rhodanine derivative, was used to decrease NAT1 activity in
MDA-MB-231 cells, breast adenocarcinoma cells. This study revealed that Rhod-o-hp inhibits
anchorage independent growth and invasiveness of MDA-MD-231 cells, which was comparable
to the effects seen with knockdown of NAT1 via shRNA, suggesting Rhod-o-hp’s effect on MDAMB-231 cells are caused by inhibition of NAT1 [40]. We have seen similar results in our lab with
the NAT1 specific small molecule inhibitor 9,10-dihydro-9,10-dioxo-1,2-anthracenediyl diethyl
ester (DDADE) [41]. DDADE was identified through an in silco screening of over 700,000 small
molecules in the ZINC (a free database of commercially-available compounds for virtual
screening) library using the crystal structure of human NAT1 to predict binding affinity. Studies in
our lab have shown that DDADE decreases NAT1 catalyzed N-acetylation and O-acetylation of
arylamine substrates in human breast adenocarcinoma cells. DDADE has also been shown to
decrease cell adhesion and cell invasion in human breast cancer cells.
Cancer cells characteristically exhibit rapid, uncontrolled growth therefore requiring
increased levels of energy and cellular components when compared to normal cells.
Reprogramming of cellular metabolism to meet these needs is one of the next generation
hallmarks of cancer proposed by Hanahan and Weinberg [52]. Although, the exact mechanism by
which cellular metabolism is reprogrammed remains unclear, it is likely specific to each type of
cancer and is also influenced by a combination of factors. Metabolomics studies are able to
generate insights into which pathways have been modified, by measuring the abundance of
metabolites and then comparing the abundances between groups with defined differences.
Historically, studies investigating the role NAT1 plays in cancer risk and progression have
focused on NAT1’s role as a xenobiotic metabolizing enzyme that can transform carcinogens, but
we propose NAT1 affects cancer risk and progression through regulation of acetyl-CoA levels in
the human body. It is our hypothesis that changing the level of NAT1 activity will lead to
alterations in the levels of acetyl-CoA. Increased NAT1 activity would lead to increased hydrolysis
of acetyl-CoA therefore less acetyl-CoA would be available. Conversely, decreased NAT1 activity
would lead to decreased hydrolysis of acetyl-CoA therefore more free acetyl-CoA would be
available. Preceding this study, metabolomics had not been utilized to investigate how differences
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in NAT1 activity alter the abundance distribution of metabolites in breast cancer cells. It is
expected that if NAT1 activity is involved in cancer risk or progression a change in metabolite
abundance distribution could be observed between breast cancer cell lines representing varying
levels of NAT1 activity. These potential changes are important to elucidate because
understanding how varying levels of NAT1 affect metabolite abundances can give us a better
understanding of which cellular pathways are altered as a result of varying levels of NAT1 activity.
An improved understanding of cellular reprogramming as a result of NAT1 activity could lead to
earlier cancer detection and more effective treatment options.
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MATERIALS AND METHODS

CONSTRUCTION OF THE THREE STABLY TRANSFECTED MDA-MB-231 CELL LINES
The breast adenocarcinoma cell line, MDA-MB-231, was purchased from ATCC
(Manassas, VA) and cultured in high-glucose Dulbecco's Modified Eagle Medium (DMEM), with
10% fetal bovine serum, 5% glutamine, and 5% penicillin/streptomycin added. The Flp-In™
System (Life Technologies, Grand Island, NY) was used previously in our lab (by Mark Doll) to
create a single Flp Recombination Target (FRT) site in the parent MDA-MB-231 cell line
according to manufacturer’s instructions. SureSilencing™ NAT1 specific shRNA plasmids and a
corresponding scrambled shRNA plasmid were purchased from SA Biosciences (Valencia, CA). It
has previously been shown that the SureSilencing™ NAT1 shRNA Clone 3 is the most effective
of the four provided by SA Biosciences at silencing NAT1 activity in the MDA-MB-231 cell line,
therefore Clone 3 was chosen as the shRNA plasmid that would be used when generating a
stable NAT1 knockdown MDA-MB-231 cell line. Next, the shRNA plasmids containing the
scrambled and NAT1 clone 3 shRNA sequences were integrated into the pcDNA5/FRT vector
from the pGeneclip™ vector, independently. For the construction of the MDA-MB-231 cell line
overexpressing NAT1, the NATb/NAT1*4 plasmid in the pcDNA5/FRT vector previously
constructed in our lab [53] was chosen. The construction of a MDA-MB-231 cell line containing a
single FRT site in the transcriptionally active region allowed us to transfect each of the plasmids
into the same genetic location in different cells, thus creating three new MDA-MB-231 cell lines
whose only difference is the level of NAT1 activity. The pcDNA5/FRT plasmids containing the
scrambled shRNA, NAT1 clone 3 shRNA plasmid or NATb/NAT1*4 overexpression plasmid, were
co-transfected into the MDA-MB-231 cell line containing the single FRT site with pOG44 (Life
Technologies), a Flp recombinase expression plasmid, using Amaxa Cell Line Nucleofector Kit V
(Lonza, Basel, Switzerland) following manufacturer’s instructions. Resulting cells were then
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cultured in complete DMEM media containing 500 µg/mL hygromycin to select for cells that had
successfully undergone transfection and stably integrated the pcDNA5/FRT plasmid into their
genomic DNA since the pcDNA5/FRT vector contains a hygromycin resistance cassette.
Hygromycin resistant colonies were selected approximately two weeks after transfection and
isolated using cloning cylinders. The resulting transformed cell lines, “Scrambled”, “Down”, and
“Up”, express parental, decreased, and increased NAT1 activity, respectively (Figure 1).
CHARACTERIZATION OF SAMPLES
Total RNA was isolated from each transformed cell line using the RNeasy Mini Kit
(Qiagen, Germantown, MD) per manufacturer’s instructions. The High Capacity Reverse
Transcriptase kit (Life Technologies, Grand Island, NY) was then used to synthesize cDNA
according to manufacturer’s instructions. NAT1 mRNA was quantitated for each transformed cell
line in triplicate using quantitative real-time polymerase chain reaction (qRT-PCR) and NAT1
specific primers and probes (Life Technologies, Grand Island, NY). The PCR conditions
suggested by the manufacturer were used.
NAT1 N-acetylation activity was measured for each transformed cell line in triplicate via
high pressure liquid chromatography (HPLC) in the presence of the NAT1 specific substrate paminobenzoic acid (PABA) by measuring the appearance of acetylated product. Cells from each
transformed cell line were collected using a cell-scraper to detach the cells from the plate and
then the cells were rinsed with 1 X PBS. Cells were then lysed in 20 mM sodium phosphate, 1
mM EDTA, 0.2% Triton X-100 (pH 7.4) with the addition of 1 mM DTT, 100 µM PMSF, 1 µg/ml
Aprotinin, and 2 µM pepstatin A. Cell lysate was centrifuged at 15,000 x g for 10 min and the
supernatant saved for subsequent NAT1 activity assays. The resulting cell lysates were
incubated with 10 µM para-aminobenzoic acid (PABA) and 100 µM acetyl-CoA at 37°C for 10
minutes. The reaction was stopped by the addition of 1 M acetic acid at a volume equal to 1/10 of
the total reaction volume. Samples were then centrifuged at 10,000 x g for 10 minutes and the
resulting supernatant was collected for analysis of N-acetyl-PABA levels via HPLC.
To determine a cell doubling rate each transformed cell line was plated at an initial
density of 25,000 cells per well in 12 well plates and then counted on a cell counter daily for 5
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Figure 1

Parent (MDA-MB-231)
Flp-In™ System (Life
Technologies, Grand Island, NY)

Parent + FRT site

Scrambled
shRNA

Scrambled
Wild-type
NAT1 activity

NAT1
Silencing
shRNA

co-transfection with a flp
recombinase expression plasmid

NAT1 Overexpression
Plasmid
hygromycin
selection

Down

Up

Decreased
NAT1 activity

Increased
NAT1 activity

Figure 1: Construction of MDA-MB-231 Breast Cancer Cells That Express Varying Levels
of NAT1 Activity
The Flp-In™ System (Life Technologies, Grand Island, NY) was used to insert a single FRT site
into the parent MDA-MB-231 cell line. The MDA-MB-231 cell line containing the FRT site was
then stably transfected with either with a plasmid containing a nonspecific shRNA plasmid into the
FRT site (Scrambled), a plasmid containing NAT1 specific shRNA into the FRT site (Down), or a
plasmid containing the NATb/NAT1*4 vector into the FRT site (Up). Each plasmid contained a
hygromycin resistant cassette therefore cells that had successfully been stably transfected were
then selected for using hygromycin
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days. Cells were plated on day 1 and allowed to adjust for 24 hours before counting on day 2.
Data were plotted to ensure cells were in the logarithmic growth phase. A cell doubling rate was
calculated for each day using Equation 1 (shown below) and then rates were averaged over the 5
day time period to get a final cell doubling rate.
Equation 1: 𝐶𝑒𝑙𝑙  𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔  𝑅𝑎𝑡𝑒 = 1/(((log 𝑏 − log  (𝑎))×3.32)/(𝑡! − 𝑡! ))
In the equation, 𝑏 = cell number on day n, 𝑎 = cell number on day n-1, 𝑡! = hours passed since
plating when cells were counted on day n, and 𝑡! = hours passed since plating when cells were
counted on day n-1.
Endogenous acetyl-CoA levels of the three transformed MDA-MB-231 cell lines were
measured in triplicate via HPLC-UV. Cells were cultured in high-glucose Dulbecco's Modified
Eagle Medium (DMEM), with 10% fetal bovine serum, 5% glutamine, and 5%
penicillin/streptomycin added in 35 mm plates to approximately 80% confluence. Medium was
then aspirated from each plate followed by a rinse with 10 mL of 1 X PBS. After removal of the
PBS, cells were released from the plate with the addition of 0.5 mL trypsin per plate and then
resuspended in 5 mL of 20% medium and 80% PBS. Cells were then counted via a Coulter
automated cell counter. Cell suspensions were then centrifuged in 15 mL tubes for 2.5 minutes at
400 X g at 4°C. Supernatant was removed and cell pellets were resuspended in 1 mL of cold
PBS. Cell suspensions were centrifuged again in 15 mL tubes for 2.5 minutes at 400 X g at 4°C.
Cells were transferred to cooled 1.5 mL eppendorf tubes by resuspending them in 1 mL of cold
PBS. Resulting cell suspensions were then centrifuged in the cold room at 300 X g for
approximately 5 minutes. Supernatant was removed and cells were lysed in 100 µL of 5% 5sulfosalicylic acid by pipetting up and down. The resulting suspension was centrifuged in the cold
room at 15,000 X g for approximately 10 minutes. Supernatant (100 µL) was collected and
injected onto a C18 reverse-phase HPLC column (250 mm × 4 mm; 5 µM pore size). Reactants
and products were separated and quantitated using a Beckman System Gold high performance
liquid chromatography (HPLC) system. HPLC separation of CoA and acetyl-CoA was achieved
using a linear gradient of 100:0 sodium phosphate (NaH2PO4) pH 4: methanol to 0:100 sodium
phosphate pH 4: methanol over 20 minutes and was quantitated by absorbance at 260 nm.
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Since the cells were lysed in 5% 5-sulfosalicylic acid, this buffer solution was used as a reference
to subtract any background acetyl-CoA coming from the lysis buffer.
METABOLOMICS
Each sample of cells for metabolomic analyses contained approximately five million cells
with a wet weight of 20 mg. The cells were lysed by homogenization in 200 µL of deionized water.
Next, samples were mixed using a vortex mixer for two minutes after the addition of 800 µL of ice
cold methanol. Samples were then stored on ice for ten minutes followed by three more minutes
of mixing on the vortex mixer. Next, samples were centrifuged at 12,000 X g for ten minutes.
Supernatant (800 µL) was then transferred to a 1.5 mL eppendorf tube and dried via speed
vacuum until dry (roughly three hours). Cell pellets used for metabolomics samples were frozen
at -80°C until day of lysis and extraction.
Polar metabolites were extracted from cell pellet samples of each transformed cell line in
octuplicate using a mixture of 80% methanol and 20% water. Samples were then derivitized with
N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) followed by GC×GC−TOF MS to
identify metabolites. The GC×GC−TOF MS data were then processed using LECO’s instrument
control software ChromaTOF for peak picking and tentative metabolite identification, followed by
retention index matching, peak merging and peak list alignment (Figure 2). Based on the results
of our analyses (described in Statistical Analysis), a list of metabolites were subject to technical
validation i.e., analysis of standards for the given metabolites on GC×GC−TOF MS and
comparison of those results to the experimental data to provide further evidence of correct
metabolite identification.
STATISTICAL ANALYSIS
One-way ANOVA was conducted on the data collected during characterization of the
transformed cell lines; Post-hoc t-tests were conducted when the one-way ANOVA statistic was
significant. The analyses were performed using Prism® software (GraphPad software, La Jolla,
CA). Two approaches were used to analyze the metabolomics data obtained, 1. univariate and 2.
multivariate/multivariable analyses (Figure 3). Imputation, normalization, and statistical
significance tests, including student’s t-tests and one-way ANOVA were performed using R
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Figure 2

Figure 2: Metabolomics Experimental Design
In this figure, Scrambled refers to the MDA-MB-231 cell line that was stably transfected with a
plasmid containing a nonspecific shRNA plasmid into the FRT site, Down refers to the MDA-MB231 cell line that was stably transfected with a plasmid containing NAT1 specific shRNA into the
FRT site, and Up refers to the MDA-MB-231 cell line that was stably transfected with a plasmid
containing the NATb/NAT1*4 vector into the FRT site. Cells from eight biological replicates of
each cell line were first harvest, counted, and lysed. Next polar metabolites were isolated,
followed by derivitization with MTBSTFA. The resulting samples were then analyzed by twodimensional gas chromatography time-of-flight mass spectrometry.
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Figure 3

Figure 3: Metabolomics Data Analyses Workflow
In this figure, the workflow for the analyses of the data collected from the two-dimensional gas
chromatography time-of-flight mass spectrometer is shown.
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software (R Core Team (2015), Vienna, Austria). Q-values for the one-way ANOVA and t-test
comparisons were computed from the raw p-values, respectively, using the R package qvalue
(John Storey, R package version 2.0.0.). To better visualize the data, volcano plots and box plots
were created using R software. Metabolite abundance fold-change between the Scrambled & Up,
Scrambled & Down, and Down & Up groups were calculated using Equation 2 (shown below).
Equation 2: 𝐹𝐶 = 2

!"#!

!
!

In the equation, 𝐹𝐶 = fold-change, 𝐴= average metabolite abundance in the reference group, 𝐵=
average metabolite abundance in the comparison group. A negative sign was added to the foldchange when metabolite abundance was lower in the comparison group compared to the
reference group. The volcano plots plot the log base 2 of the fold change between the two
specific groups versus the negative log base 10 of the unadjusted student’s t-test p-value
between the two specific groups. The box plots plot the median normalized abundance levels for
each metabolite. Then, Principal Component Analysis (PCA), Partial Least Squares Discriminate
Analysis (PLS-DA), and Orthogonal Partial Least Squares Discriminate Analysis (OPLS-DA) were
conducted to give a more complete picture of metabolite interactions. The loadings of Component
1 from the OPLS-DA results were plotted to visualize which metabolites were contributing the
most to the separation of the groups.
PATHWAY ANALYSIS
Pathway analysis was conducted on only those metabolites that were verified and found
to be significant following student’s t-tests and/or one-way ANOVA. We began the pathway
analysis portion of this study by first locating acetyl-CoA on the Roche Biochemical Pathways
Chart (F. Hoffmann-La Roche AG, Basel, Switzerland) and then following all possible pathways to
and from acetyl-CoA to locate the metabolites that were verified and significant. Some
metabolites were not located in a pathway involving acetyl-CoA therefore they have not been
considered further at this time. For those that were located in a pathway involving acetyl-CoA, we
then developed hypotheses that could explain how each metabolite’s abundance distribution
across the three groups related to the amount of free acetyl-CoA available.
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RESULTS

CHARACTERIZATION OF SAMPLES
Three stably transfected MDA-MB-231 cell lines, Scrambled, Up, and Down, expressing
parental, increased, and decreased levels of NAT1 activity, respectively, have been constructed.
The three cell lines were characterized to confirm we had successfully constructed stable cell
lines that express parental, increased, and decreased NAT1 activity relative to the parent MDAMB-231 cell line. First, the levels of NAT1 mRNA were measured via quantitative real-time PCR
with NAT1 specific primers and probes. Differences in NAT1 mRNA expression of the Parent,
Scrambled, Down, and Up cell lines were tested by one-way ANOVA (p<0.0001) and found to be
statistically significant (Figure 4). The NAT1 mRNA of the parent MDA-MB-231 cell line that
contains the FRT site but was not transfected with shRNA plasmids was measured and found to
express 90% of the NAT1 mRNA that the Scrambled cell line does. This difference in NAT1
mRNA between the Parent and Scrambled cell lines was not statistically significant (p>0.05)
when tested further by a Tukey’s post-hoc test. Relative to the Scrambled cell line, the Down cell
line expressed 50% of the NAT1 mRNA and the Up cell line expressed 3100% of the NAT1
mRNA. Following a Tukey’s post-hoc test NAT1 mRNA expression was significantly different
between the Scrambled & Up (p ≤ 0.001) and Down & Up (p ≤ 0.001) cell lines but not between
the Scrambled & Down cell lines (p>0.05).
Next, the levels of NAT1 activity were measured via detection of acetylated product by
HPLC using the NAT1 specific substrate PABA. Differences in NAT1 PABA acetylation activity of
the Parent, Scrambled, Down, and Up cell lines were tested by one-way ANOVA (p<0.0001) and
found to be statistically significant (Figure 5). The parent MDA-MB-231 cell line, that contains only
the FRT site, was found to have a NAT1 activity of 19.2 ± 1.2 nmol PABA acetylated/min/mg
protein. The Scrambled cell line, that contains the FRT site and was transfected with the NAT1
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Figure 4

NAT1 mRNA Expression
One-way ANOVA p<0.0001

Relative mRNA Expression
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Figure 4: NAT1 mRNA expression of MDA-MB-231 transformed cell lines.
In this figure, Scrambled refers to the MDA-MB-231 cell line that was stably transfected with a
plasmid containing a nonspecific shRNA plasmid into the FRT site, Down refers to the MDA-MB231 cell line that was stably transfected with a plasmid containing NAT1 specific shRNA into the
FRT site, and Up refers to the MDA-MB-231 cell line that was stably transfected with a plasmid
containing the NATb/NAT1*4 vector into the FRT site. Relative NAT1 mRNA levels in cell lines
normalized to scrambled shRNA cell line. Bars represent results from three separate
determinations with mean ± SD. Statistical significance was determined using one-way ANOVA
with p<0.0001 followed by a Tukey’s post-hoc test. NS = not significant, *** = p ≤ 0.001.
.
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Figure 5

NAT1 Acetylation Activity
One-way ANOVA p<0.0001

PABA Activity
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Figure 5: NAT1 PABA acetylation activity of MDA-MB-231 transformed cell lines.
PABA N-acetyltransferase activity of transformed cell line lysates were measured via HPLC. In
this figure, Scrambled refers to the MDA-MB-231 cell line that was stably transfected with a
plasmid containing a nonspecific shRNA plasmid into the FRT site, Down refers to the MDA-MB231 cell line that was stably transfected with a plasmid containing NAT1 specific shRNA into the
FRT site, and Up refers to the MDA-MB-231 cell line that was stably transfected with a plasmid
containing the NATb/NAT1*4 vector into the FRT site. Bars represent results from three separate
determinations with mean ± SD. Statistical significance was determined using one-way ANOVA
(p<0.0001) followed by a Tukey’s post-hoc test. NS = not significant, *= ≤ 0.05,
*** = p ≤ 0.001.
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scrambled shRNA, was found to have a NAT1 activity of 18.9 ± 0.2 nmol PABA
acetylated/min/mg protein. The Up cell line, that contains the FRT site and was transfected with
the NATb/NAT1*4 overexpression plasmid, was found to have a NAT1 activity of 233.9 ± 2.2
nmol PABA acetylated/min/mg protein. Finally, the Down cell line, that does contain the FRT site
and was transfected with the NAT1 clone 3 shRNA, was found to have a NAT1 activity of 11.6 ±
0.6 nmol PABA acetylated/min/mg protein. When compared to the Scrambled cell line, the Down
cell line had 61% of the NAT1 activity and the Up cell line had 1240% of the NAT1 activity.
Following a Tukey’s post-hoc test the NAT1 activity of the parent MDA-MB-231 cell line that
contains the FRT site but was not transfected with shRNA plasmids did not significantly vary
(p>0.05) in activity from the NAT1 activity of the Scrambled cell line. Further analysis does not
include the parent MDA-MB-231 cell line since there was no statistically significant difference
between its levels of NAT1 mRNA & NAT1 activity and that of the Scrambled cell line.
Next, the doubling times of the three cell lines were measured by counting the cells over
a period of 6 days. The doubling rate of the Scrambled, Up, and Down cell lines were calculated
to be 27.4 ± 0.3 hours, 23.9 ± 1.2 hours, and 27.2 ± 2.4 hours, respectively. Following a one-way
ANOVA (p=0.3850) the doubling rates of the three transformed cell lines were not found to be
significantly different (Figure 6). Finally, endogenous acetyl-CoA levels were measured via HPLCUV. Differences in endogenous acetyl-CoA levels were tested by one-way ANOVA (p=0.0218)
and found to be statistically significant (Figure 7). The acetyl-CoA levels of the Scrambled, Up,
and Down transformed cell lines were found to be 0.046 ± 0.0025 nmoles acetyl-CoA/1,000,000
cells, 0.031 ± 0.0026 nmoles acetyl-CoA/1,000,000 cells, and 0.049 ± 0.0072 nmoles acetylCoA/1,000,000 cells, respectively. Tukey’s post-hoc test showed that only the difference in
endogenous acetyl-CoA levels between the Down and Up group was statistically significant (p <
0.05).
METABOLOMICS
All metabolites were given a metabolite number (arbitrarily) to provide a unique
identification since some metabolites appeared multiple times and others were unnamed. Of all
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Figure 6

Doubling Time of Transformed MDA-MB-231
Cell Lines
Doubling Time (Hours)
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Figure 6: Doubling Time of MDA-MB-231 transformed cell lines.
Determination of doubling time in the transformed cell lines. In this figure, Scrambled refers to the
MDA-MB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231
cell line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has
increased NAT1 activity. Bars represent results from three separate determinations with mean ±
SD. Statistical significance was tested by one-way ANOVA (p=0.3850).
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Figure 7

Endogenous Acetyl-CoA Levels
One-way ANOVA p = 0.0218
NS
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Figure 7: Endogenous Levels of Acetyl-CoA in the Three Transformed MDA-MB-231 Cell
Lines.
Endogenous levels of acetyl-CoA were measured in via HPLC-UV in the three transformed MDAMB-231 cell lines. In this figure, Scrambled refers to the MDA-MB-231 cell line that has parental
levels of NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased NAT1
activity, and Up refers to the MDA-MB-231 cell line that has increased NAT1 activity. The bars
represent results from a single determination in triplicate in nanomoles of acetyl-CoA per one
million cells ± standard deviation. Bars represent results from a single determination. Statistical
significance was tested by one-way ANOVA (p=0.0218) followed by a Tukey’s post-hoc test. NS
= not significant, *= ≤ 0.05
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metabolites detected by GC×GC−TOF MS, 52.3% were tentatively identified based on mass
spectrum and retention index matching. Following student’s t-tests, 8.3% of metabolites detected
by GC×GC−TOF MS had a p-value ≤ 0.05 and were verified with standards (Table 1). Most of
these metabolites are amino acids. Two metabolites, L-asparagine and palmitoleic acid, were
found to be significant across two student’s t-test comparisons. Following a one-way ANOVA,
29.0% of tentatively identified metabolites had a p ≤ 0.05. After technical validation, only 7.6% of
metabolites had a one-way ANOVA p ≤ 0.05 and were verified with standards (Table 2). Of the
metabolites we submitted for technical validation, 52.3% were either misidentified or had no
standard available for comparison (Table 3).
After stratification of the metabolites by student’s t-test p-value and fold-change via
volcano plots, it was observed that L-asparagine and trans-9-octadeconic acid had both a p-value
≤ 0.05 and a fold-change of at least ± 1.5 between the Scrambled and Down groups (Figure 8);
between the Scrambled and Up groups, L-threonine, palmitoleic acid, and L-asparagine had both
a p-value ≤ 0.05 and a fold-change of at least ± 1.5 (Figure 9). From the volcano plot comparing
the Down and Up groups, L-threonine, palmitoleic acid, and L-ornithine had both a p-value ≤ 0.05
and a fold-change of at least ± 1.5 (Figure 10). In the volcano plots, only those metabolites that
had a both a p-value ≤ 0.05 and a fold-change of at least ± 1.5 were labeled.
Box plots were created for all metabolites that were identified to be significant and had a
fold change of ± 1.5 between at least 2 of the groups. The metabolites L-leucine, L-aspartic acid,
and L-valine display the same abundance distribution pattern between the Scrambled, Down, and
Up groups (Figure 11). The Down group has the lowest abundance, the Scrambled group has a
mid-level abundance, and the Up group has the highest abundance. The box plot for palmitoleic
acid shows that the Up group has the lowest abundance while the Scrambled group has the
highest abundance (Figure 12). Of the seven amino acids that are degraded to acetyl-CoA, only
leucine, tyrosine, and threonine were verified with standards and showed a significant difference
in abundance distribution between the three groups (Figure 13).
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Table 1
Metabolite
#
Up vs
Down*

Down vs
#
Scrambled
Up vs
$
Scrambled

M73
M96
M102
M66
M69
M103
M106

Metabolite
L-threonine
L-aspartic acid
palmitoleic acid
L-valine
L-leucine
L-ornithine
L-asparagine
trans-9octadecenoic acid
L-threonine
palmitoleic acid
L-asparagine

M113
M73
M102
M106

1t

2t

R (s)

R (s)

t-test
p-value

t-test
q-value

Fold
Change

0.0006
0.0008
0.006
<0.0001
0.0003
0.03
0.002

0.01
0.01
0.04
0.004
0.008
0.1
0.02

-1.64
1.44
-1.40
1.36
1.27
1.73
-1.54

1744.578695
2243.252686
2375.717124
1640
1693.142084
2376.053736
2395.754445

0.991514109
0.991516707
1.043582822
0.9275
0.91843099
0.962442604
1.064343458

72-19-5
56-84-8
373-49-9
72-18-4
61-90-5
70-26-8
70-47-3

0.01

0.07

-1.90

2573.274268

1.091159053

112-79-8

0.0009
0.001
0.002

0.01
0.02
0.02

-1.62
-1.57
-1.53

1744.578695
2375.717124
2395.754445

0.991514109
1.043582822
1.064343458

72-19-5
373-49-9
70-47-3

CAS no.

!
Table 1: Metabolites Altered by an Increase or Decrease in NAT1 Activity in Breast Cancer
Cells
Metabolites differed significantly between designated groups following student’s t-test, and were
technically validated. *Down is the reference group, therefore a positive fold change indicates that
metabolite was higher in the Up group whereas a negative value indicates the metabolite was
#

lower in the Up group. Scrambled is the reference group, therefore a positive fold change
indicates that metabolite was higher in the Down group whereas a negative value indicates the
$

metabolite was lower in the Down group. Scrambled is the reference group, therefore a positive
fold change indicates that metabolite was higher in the Up group whereas a negative value
indicates the metabolite was lower in the Up group. ANOVA q-values were calculated to adjust pvalues for the multiple comparisons we are testing.1tR is the first dimension retention time in
seconds and 2tR is the second dimension retention time. The CAS number is a unique numerical
identifier assigned to chemical compounds by the Chemical Abstracts Service (CAS).
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Table 2

Metabolite #

Metabolite

ANOVA
p-value

ANOVA
q-value

M73
M106
M66
M69
M96
M84
M102
M65
M77
M80

L-threonine
L-asparagine
L-valine
L-leucine
L-aspartic acid
L-methionine
palmitoleic acid
beta alanine
L- proline
glycerol

0.0002
0.002
<0.0001
<0.0001
0.0008
0.05
0.0001
0.03
0.04
0.02

0.0009
0.003
0.0004
0.0004
0.002
0.03
0.0006
0.02
0.03
0.02

1t (s)
R

2t (s)
R

CAS no.

1744.578695
2395.754445
1640
1693.142084
2243.252686
2034.28795
2375.717124
1626
1789.30765
1921.391

0.991514109
1.064343458
0.9275
0.91843099
0.0.991516707
1.052523863
1.0435882822
0.96
1.01797484
0.87520052

72-19-5
70-47-3
72-18-4
61-90-5
56-84-8
63-68-3
373-49-9
107-95-9
147-85-3
56-81-5

!
Table 2: Metabolites Altered by an Increase and Decrease in NAT1 Activity in Breast
Cancer Cells
Ten metabolites were found to differ significantly following a one-way ANOVA and were also
technically validated with standards. These metabolites were included in subsequent pathway
analysis. ANOVA q-values were calculated to adjust p-values for the multiple comparisons we are
testing. 1tR is the first dimension retention time in seconds and 2tR is the second dimension
retention time. The CAS number is a unique numerical identifier assigned to chemical compounds
by the Chemical Abstracts Service (CAS).
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Table 3
Verification
Status

Metabolite

Metabolite #

V

L-glutamine

M112

2519.1796

1.0830347

V
V

L-threonine

M73
M86

1744.578695
2097.140471

0.991514109
0.934089146

V

M106

2395.754445

1.064343458

M113

2573.274268

1.091159053

V
V

L-asparagine
trans-9-octadecenoic
acid
L-valine
L-leucine

M66
M69

1640
1693.142084

0.9275
0.91843099

V

L-aspartic acid

M96

2243.252686

0.991516707

V

L-tyrosine

M119

2748

1.28

V
V

L-methionine
palmitoleic acid

M84
M102

2034.28795
2375.717124

1.052523863
1.043582822

V

malic acid

M94

2195.57733

0.9831648

V

fumaric acid

M78

1827.812518

0.97596729

V
V

beta-alanine
succinic acid

M65
M75

1626
1783.060069

0.96
1.017216049

V

citric acid

M117

2712

1.15

V

L-alanine

M57

1483.14905

0.925

V
V

pidolic acid
L-proline

M83
M77

2016.031208
1789..30765

1.15
1.01797484

V

R (s)

2t

R (s)

V

glycerol

M80

1921.391

0.87520052

V

L-ornithine

M103

2376.053736

0.962442604
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Table 3-Continued

	
  
U
U

phosphoric acid

M87
M88

2109.995458
2069.295505

0.914484667
0.938482329

U

M93

2098.260648

0.924620606

U

M99

2313.63

1.039414761

U
U

M105
M107

2420.345586
2428.017212

0.795902017
0.791466107

U

M115

2664.376829

1.095429665

U

M128

1996.460852

0.989310526

U
U

M129
M41

2063.537718
1194

0.943364826
1.005

M131

3135.889469

1.344001898

M132

3141.608204

1.362317152

2415.504303
1056.667071

1.335384303
0.961182658

U

4-bromobutan-1-ol
cholesterol

U
U
U

adenine
8-chlorooctan-1-ol

M108
M123

M

L-glutamine

M116

2696.95982

1.052917405

M

oxalic acid

M92

2186.059441

1.025892253

M
M

malic acid

M47
M120

1277.936778
2769.82079

0.848586571
1.149911156

M

M109

2436.8759

0.93113281

M

beta-alanine

M79

1891.871716

1.073551252

M
M
M

pidolic acid

M90
M100
M110

2242.519873
2353.592825
2478.422412

0.954952753
0.888429472
0.977623334

L-lysine

Table 3: Tentatively Identified Metabolites Altered by Increased and/or Decreased NAT1
Activity Subjected to Technical Validation
V = verified with standards
U = standard unavailable
M = retention time does not match standard therefore misidentified
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Figure 8
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Figure 8: Volcano plot comparing metabolite fold-change and student t-test unadjusted pvalue between the Scrambled and Down transformed cell lines.
Fold-change of metabolite abundance was calculated and plotted versus unadjusted student’s ttest p-values to compare the transformed cell lines. In this figure, Scrambled refers to the MDAMB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell
line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has
increased NAT1 activity. Metabolites located at the top left and top right of the plot indicate that
metabolite has both a substantial fold-change and a significant p-value. The dotted vertical blue
lines indicate a fold-change of ± 1.5.
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Figure 9

Scrambled vs Up Volcano Plot
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Figure 9: Volcano plot comparing metabolite fold-change and student t-test unadjusted pvalue between the Scrambled and Up transformed cell lines.
Fold-change of metabolite abundance was calculated and plotted versus unadjusted student’s ttest p-values to compare the transformed cell lines. In this figure, Scrambled refers to the MDAMB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell
line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has
increased NAT1 activity. Metabolites located at the top left and top right of the plot indicate that
metabolite has both a substantial fold-change and a significant p-value. The dotted vertical blue
lines indicate a fold-change of ± 1.5.
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Figure 10
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Figure 10: Volcano plot comparing metabolite fold-change and student t-test unadjusted pvalue between the Down and Up transformed cell lines.
Fold-change of metabolite abundance was calculated and plotted versus unadjusted student’s ttest p-values to compare the transformed cell lines. In this figure, Scrambled refers to the MDAMB-231 cell line that has parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell
line that has decreased NAT1 activity, and Up refers to the MDA-MB-231 cell line that has
increased NAT1 activity. Metabolites located at the top left and top right of the plot indicate that
metabolite has both a substantial fold-change and a significant p-value. The dotted vertical blue
lines indicate a fold-change of ± 1.5.
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Figure 11

Relative Abundance
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Figure 11: Box Plots Comparing the Abundance of Specific Metabolites Between the
Transformed Cell Lines.
Box plots showing the abundance distribution of the metabolites L-leucine, L-aspartic acid, and Lvaline in the three groups In this figure, Scrambled refers to the MDA-MB-231 cell line that has
parental levels of NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased
NAT1 activity, and Up refers to the MDA-MB-231 cell line that has increased NAT1 activity.
Abundances were median scaled for each metabolite. The solid black dots represent the mean
and the open dots represent outliers. These three metabolites all follow the same pattern of
abundance distribution.
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Figure 12
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Figure 12: Box Plot Comparing the Abundance of the Metabolite Palmitoleic Acid Between
the Transformed Cell Lines.
Box plot showing the abundance distribution of the metabolite palmitoleic acid in the three
groups. In this figure, Scrambled refers to the MDA-MB-231 cell line that has parental levels of
NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased NAT1 activity, and
Up refers to the MDA-MB-231 cell line that has increased NAT1 activity. The solid black dots
represent the mean and the open dots represent outliers. Abundances were median scaled.
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Figure 13
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Figure 13: Box Plot of Amino Acids that are Broken Down to Form Acetyl-CoA.
Box plot showing the abundance distribution of amino acids that are degraded to form acetylCoA. In this figure, Scrambled refers to the MDA-MB-231 cell line that has parental levels of
NAT1 activity, Down refers to the MDA-MB-231 cell line that has decreased NAT1 activity, and
Up refers to the MDA-MB-231 cell line that has increased NAT1 activity. The solid black dots
represent the mean and the open dots represent outliers. Abundances were median scaled for
each metabolite. L-leucine and L-tyrosine exhibit the same distribution pattern with metabolite
levels increased in the Up group when compared to the Scrambled and Down groups. The two Lthreonine box plots represent different derivitizations of that amino acid.
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MULTIVARIATE/MULTIVARIABLE ANALYSIS
The goal of using multivariate/multivariable analyses methods is to identify groups of
metabolites that, together, are driving between group variation versus within-group variation.
Principal Component Analysis (PCA) was the first multivariate approach used. Principal
component 1 (PC1) of PCA separated the Down group from the Scrambled and Up groups but
two component PCA did not discriminate between the Scrambled and Up groups (Figure 14).
Therefore, Partial Least Squares- Discriminate Analysis (PLS-DA) methods were used in an
attempt to achieve separation between all three groups with a single principle component. Two
component PLS-DA led to complete group separation but within group variation and between
group variation were both contributing to each component (Figure 15). We then proceeded to the
multivariate analysis method, Orthogonal Partial Least Squares- Discriminate Analysis (OPLSDA). Two component OPLS-DA showed complete group separation with component 1 explaining
group predictive variation and component 2 explaining variation uncorrelated with group
membership (Figure 16). Since component 1 of the OPLS-DA showed complete group
separation, the loadings of that component were plotted to show which metabolites were
contributing the most to the separation (Figure 17). The loadings of component 1 from OPLS-DA
show that L-threonine, L-glutamine, and oxalic acid are driving the separation between the groups
and are higher in the Down group and conversely lower in the Up group. The loadings of
component 1 from OPLS-DA also show L-valine, L-leucine, and L-aspartic acid are driving the
separation between the groups but are higher in the Up group and conversely lower in the Down
group.
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Figure 14
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Figure 14: Principal Component Analysis (PCA) Scores Plot
Two component PCA explains 40% of the total variance. In this figure, S (in black) refers to the
MDA-MB-231 cell line that has parental levels of NAT1 activity, D (in blue) refers to the MDA-MB231 cell line that has decreased NAT1 activity, and U (in red) refers to the MDA-MB-231 cell line
that has increased NAT1 activity. The number following each letter indicates the individual
sample number. Each component on the axes represents a linear combination of all metabolites.
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Figure 15
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Figure 15: Partial Least Squares-Discriminate Analysis (PLS-DA) Scores Plot
Two component PLS-DA showed separation between the groups. In this figure, S (in black) refers
to the MDA-MB-231 cell line that has parental levels of NAT1 activity, D (in blue) refers to the
MDA-MB-231 cell line that has decreased NAT1 activity, and U (in red) refers to the MDA-MB231 cell line that has increased NAT1 activity. The number following each letter indicates the
individual sample number. Each component represents a linear combination of all metabolites.
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Figure 16:

All Groups OPLS−DA

4

U3
U8
U5
D3D8
D1

2

U6

D7

U4
D5

D4
D2

0

U1

−2

Component 2

U2

−4

S6

−6

S5
S7

S2 S3 S1
−6

−4

−2

0

2

4

6

Component 1

Figure 16: Orthogonal Partial Least Squares Discriminate Analysis (OPLS-DA) Scores Plot
OPLS-DA achieved complete separation between all groups. In this figure, S (in black) refers to
the MDA-MB-231 cell line that has parental levels of NAT1 activity, D (in blue) refers to the MDAMB-231 cell line that has decreased NAT1 activity, and U (in red) refers to the MDA-MB-231 cell
line that has increased NAT1 activity. The number following each letter indicates the individual
sample number. Each component represents a linear combination of all metabolites.
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Figure 17: Jack-knife loadings plot for component 1 of the OPLS-DA.

The metabolites at the extremes of the plot are the largest contributors to the separation of the

groups. Error bars represent mean ± SD.
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DISCUSSION

The purpose of this study was to identify metabolic changes induced by varying levels of
human NAT1 in MDA-MB-231 breast cancer cells. It is our hypothesis that changing the level of
NAT1 activity will lead to alterations in the levels of acetyl-coenzyme A (acetyl-CoA). Increased
NAT1 activity would lead to increased hydrolysis of acetyl-CoA therefore less free acetyl-CoA
would be available. Conversely, decreased NAT1 activity would lead to decreased hydrolysis of
acetyl-CoA therefore more free acetyl-CoA would be available. It is our hypothesis that due to
fluctuations in the amount of free acetyl-CoA available, cellular pathways will be altered. AcetylCoA is a central mediator of many cellular pathways (Figure 18).
Many of the breast cancer cell lines used in research have innately different levels of
human NAT1 activity. Wakefield et al. have reported that the NAT1 activity in breast cancer cell
lines range from 0.1 ± 0.02 nmol PABA acetylated/min/mg protein in Cal51 cells to 202.2 ± 28
nmol PABA acetylated/min/mg protein in ZR-75-1 cells [34]. With our transformed MDA-MB-231
cell lines, not only do they express varying levels of NAT1 activity, ranging from 11.6 ± 0.6 nmol
PABA acetylated/min/mg protein in the Down cell line to 233.9 ± 2.2 nmol PABA
acetylated/min/mg protein in the Up cell line, but they also have the same genetic background.
This removes any confounding factors due to genetic differences that would arise if we performed
this same study using the cell lines that innately have different NAT1 activity. Ideally, we wanted
the Down cell line to have little to no NAT1 activity but when utilizing shRNA that targets NAT1
the most we have been able to knock-down NAT1 activity has been by 50% when compared to
the parent cell line. We have recently constructed two MDA-MB-231 complete NAT1 knockout
cell lines in our lab using the CRISPR® system that will be used in further studies (see future
directions for more details).
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Figure 18

http://employees.csbsju.edu/hjakubowski/classes/ch
331/Metabolism/MetPathways5_RegKeyEnz.html

	
  

Figure 18- Acetyl-CoA is a Central Molecule Involved in a Plethora of Reactions.
Acetyl-CoA is a central molecule involved in many pathways including fatty acid synthesis and
degradation, the citric acid cycle (TCA Cycle), and ketone body and isoprenoid synthesis.
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In our characterization of the transformed cell lines, we found that relative to the
Scrambled cell line, the Down cell line expressed 50% of the NAT1 mRNA and the Up cell line
expressed 31 times the NAT1 mRNA. We also found that the Down cell line had 61% of the
NAT1 activity and the Up cell line had 1240% the NAT1 activity of the Scrambled cell line. The
difference in NAT1 mRNA expression between the Scrambled and Down groups was not
statistically significant by a Tukey’s post-hoc test but, the difference in NAT1 activity between the
Scrambled and Down groups was statistically significant by a Tukey’s post-hoc test. We postulate
that this is due to the difference in standard error of the mean (SEM) between the two
measurements. The SEM is much larger for the NAT1 mRNA measurement in the Scrambled
group when compared to the SEM for the NAT1 activity measurement in the same group.
When we began this study it was our hypothesis that changing the level of NAT1 activity
would change the level of free acetyl-CoA available and this change in acetyl-CoA levels would
thus induce alterations in cellular pathways. In this study we observed that the levels of
endogenous acetyl-CoA are decreased in the transformed MDA-MB-231 cell line expressing
increased NAT1 acetylation activity when compared to the transformed MDA-MB-231 cell line
expressing parental levels of NAT1 acetylation activity. This is the first study to compare
endogenous levels of acetyl-CoA in samples that express varying levels of NAT1. This finding,
combined with our original hypothesis, led us to begin the pathway analysis portion of this study
by first following pathways that involved acetyl-CoA and identifying where the metabolites that
were classified as significant and were verified with standards were located in those pathways.
We then applied our hypothesis to see if the change in abundance of metabolite were biologically
plausible. In the metabolomics portion of this study, the abundance of palmitoleic acid was shown
to be decreased in the Up group when compared to the Scrambled group with a student’s t-test pvalue < 0.005 and a fold change of 1.57. Our refined hypothesis is that in the Up group, acetylCoA hydrolysis by NAT1 is increased when compared to the Scrambled group, leaving less free
acetyl-CoA available for other reactions.
We expected to see an increase in the flux of acetyl-CoA through the fatty acid synthesis
pathway in the cell line that had increased NAT1 activity since cancer cells require increased
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amounts of cellular components and energy due to their rapidly dividing nature and
overexpression of NAT1 in cell lines has been shown to increase cell growth and invasion. The
fatty acid synthesis pathway (Figure 19) begins with the synthesis of malonyl-CoA by acetyl-CoA
carboxylase (ACC) from acetyl-CoA and bicarbonate. Acetyl-CoA carboxylase (ACC) is a biotindependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to
produce malonyl-CoA through its two catalytic activities. In the next step of fatty acid synthesis,
malonyl-CoA and acetyl-CoA are combined by fatty acid synthase I (FAS1) to form palmitate
(16:0). Palmitate is a branch point in the fatty acid synthesis pathway. Either stearate (18:0) or
9

palmitoleic acid (16:1 (Δ )) can be synthesized from palmitate. Palmitoleic acid is synthesized
from palmitate by fatty acyl-CoA desaturase. Palmitate negatively feeds back on acetyl-CoA
carboxylase (ACC) thus preventing further palmitate generation. In this study we saw a decrease
9

in the abundance of palmitoleic acid (16:1 (Δ )) when NAT1 activity was increased. We now
propose that the abundance of palmitoleic acid is decreased in the cell line that has increased
NAT1 activity because there is less free acetyl-CoA available therefore palmitate is selectively
shunted to the other branch of the fatty acid synthesis pathway, which synthesizes stearate. To
test this we need to measure the levels of stearate to see how they compare between the three
cell lines.
There are seven amino acids that are degraded to acetyl-CoA; these amino acids are 1.
tryptophan, 2. lysine, 3. phenylalanine, 4. tyrosine, 5. leucine, 6. isoleucine, and 7. threonine. If
our hypothesis that different levels of human NAT1 in the MDA-MB-231 cells lead to altered
levels of acetyl-CoA and these altered levels of acetyl-CoA lead to alterations in cellular pathways
is correct, it is plausible that there could be increased or decreased degradation of one or more of
these seven amino acids to compensate for the altered levels of acetyl-CoA. In our data, leucine,
tyrosine, and threonine were verified with standards and showed a significant difference in
abundance distribution between the three groups. Of those three amino acids, leucine and
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Figure 19
Acetyl-CoA + HCO3Acetyl-CoA Carboxylase

Malonyl-CoA + Acetyl-CoA

Fatty Acid Synthase I

Palmitate (16:0)
Fatty Acyl-CoA
Desaturase

elongation

Stearate (18:0)

desaturation

Oleate (18:1)

Palmitoleic Acid (16:1)

elongation

Longer Saturated
Fatty Acids

Figure 19: Abbreviated Fatty Acid Synthesis Pathway.
This pathway shows the utilization of Acetyl-CoA in the fatty acid synthesis pathway. Palmitoleic
acid is synthesized from palmitate by the enzyme fatty acyl-CoA desaturase. Palmitate can also
be elongated to form stearate which can then be further elongated to form longer saturated fatty
acids. The numbers in parentheses next to the names of the fatty acids are lipid numbers which
have the form C:D, where C is the number of carbon atoms and D is the number of double bonds
in the fatty acid.
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tyrosine had the same relative abundance distribution suggesting there may be a shared
mechanism by which these metabolites are being regulated.
As with any study involving a high number of comparisons, there is the chance that some
of the observed changes in abundance of metabolites are due to random chance. We have
decreased the likelihood of pursuing metabolites where this may be the case by choosing
metabolites for further investigation that are involved in pathways that also involve acetyl-CoA. By
doing this we can develop a rationale for why the abundance of that metabolite would be changed
between cells expressing varying levels of NAT1 activity.
In the metabolomics data there were several misidentified metabolites that were both
statistically significant and had a fold change of 1.5 or greater. One such metabolite, M116, with a
one-way ANOVA p < 0.0001 was initially identified as L-glutamine but was later shown to be
misidentified when compared to the L-glutamine standard. Unfortunately, there is currently not a
way for us to retroactively identify these metabolites; we can only see that they are misidentified.
As a result we may be missing important metabolites that could provide a key link between
varying levels of NAT1 and altered cellular metabolism. As the field of metabolomics progresses,
libraries containing spectral data of metabolites will become more complete and lead to a larger
number of identified metabolites in future studies.
If our proposed hypothesis holds true, we would expect the abundance distribution of any
metabolite that is changed, as a result of the level of NAT1 activity, to show the Scrambled group
in the middle with the Up and Down groups above and below or below and above. This is not
necessarily true though as there may be compensatory mechanisms that are regulating the
amount of acetyl-CoA. Also, there may be a threshold in the amount of acetyl-CoA that must be
altered in order for a change in metabolite abundance to be observed.
Another concern in metabolomics studies is the threshold of detection. Some metabolites
are present in cells at levels that are too small to be accurately measured or even detected but
that does not mean the abundance of those metabolites are not changing. A small change in
these metabolites could have a greater impact than metabolites that are present in the cells at
higher abundances and can be easily measured.
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SUMMARY AND CONCLUSIONS

STRENGTHS OF THIS WORK
The construction of three stably transfected cell lines provided stable breast cancer cell
line models whose only genetic difference is the level of human NAT1 activity. Before the
construction of these cell lines, comparison between cell lines that expressed different levels of
NAT1 activity was limited to evaluating cell lines whose endogenous NAT1 activity varied. In the
cell lines that endogenously express varying levels of NAT1 activity there are also other
differences that have to be taken into account, including mutation differences such as estrogen
receptor (ER), progesterone receptor (PR), and Her2/neu status, among many others, when
comparing the results of those studies. With these new cell lines, the effect NAT1 activity has on
cancer progression can be more thoroughly evaluated with less confounding factors. We have
utilized this advantageous new resource to show for the first time that endogenous acetyl-CoA
levels vary between samples whose only difference is the level of NAT1 activity. Acetyl-CoA is a
central molecule involved in a plethora of reactions, including fatty acid synthesis and the TCA
cycle.
Also, this study is the first to investigate the effect of varying human NAT1 activity on the
metabolome of a breast cancer cell line. Metabolomics has developed into an extremely
beneficial and information-rich area of research as of late, but has been under-utilized in regards
to research on the NAT isozymes. Analysis of metabolomics data can help reveal what pathways
are altered as a result of varying levels of NAT1 activity thus providing insights into the role NAT1
has in breast cancer disease and progression. A greater understanding of the role NAT1 has in
breast cancer could lead to better detection and treatment methods.
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CAVEATS AND WEAKNESSES
MDA-MB-231 triple-negative breast cancer cells were chosen for manipulation of NAT1
activity and subsequent analyses in this study. MDA-MB-231 cells are known to have mutations
in 5 genes, including BRAF, CDKN2A, KRAS, NF2, and TP53. These mutations may complicate
evaluation of the effect NAT1 has on cancer risk. Since these cells are already cancerous in
nature, evaluating the risk NAT1 levels play in cancer risk is muddled at best. A fundamental
complementation to this study would include the manipulation of human NAT1 activity in other
breast cancer cell lines and cells from normal breast tissue.
Comparison of NAT1 activity between the three transformed cell lines revealed that while
the Up cell line has approximately thirteen times the NAT1 activity of the Scrambled cell line, the
NAT1 activity in the Down cell line is only decreased by approximately 50%. The difference in
NAT1 activity between the Scrambled and Up cell lines is so drastic that it may overshadow
differences between the Scrambled and Down cell lines. Comparison of endogenous acetyl-CoA
levels also only showed a statistically significant difference between the Scrambled and Up cell
lines. We were hoping to completely knockdown the NAT1 activity in our down cell line however
an approximate 50% decrease in activity was the most that could be achieved when utilizing our
methods. Additional methods that knockout rather than knockdown the NAT1 gene have helped
us achieve a cell line with no NAT1 activity, that will be used in future studies.
An additional caveat to this study is the use of cell lines as opposed to patient derived
tumor samples. Tumors are not made up of a single cell-type but multiple cell types that each
play a unique role while cell lines are a homogenous collection of cells. Also, these multiple cell
types found in tumors exist in a tumor micro-environment (TME) that plays a big role in cancer
progression. It has been shown that cancer cells secrete paracrine growth factors that recruit
stromal cells then the stromal cells secrete cytokines which accelerate the aggressiveness of
cancer cells [54]. It has also been shown that the TME allows complex metabolic interactions
between the tumor and surrounding cell types. Unfortunately, since we are using cell lines as our
samples in this study, we may be missing out on important metabolic changes due to the TME.

	
  

46

The samples prepared for metabolomics were not incubated with any NAT1 substrates.
Humans are exposed to NAT1 substrates frequently, therefore the condition under which the cells
were collected may not represent the most biologically relevant conditions. However, this does
allow us to investigate a possible endogenous role for NAT1. Fellow researchers who work with
NAT1 have postulated that NAT1 has an undiscovered endogenous role given that it is distributed
throughout most tissues of the body and found in almost every species.
In cell lines, metabolites can be found both within the cells themselves and also within the
medium the cells have been cultured in since some metabolites are excreted from the cells. In
this study we chose to collect only the cell pellets for metabolomics sample preparation and
discarded the media they were cultured in. The metabolites excreted into the culture medium may
also provide valuable insights into cellular pathway alternations that were missed by analyzing
metabolites from cell pellets only. We may have missed important differences in the metabolites
that were excreted into the media.
In this study we only extracted and examined polar metabolites from the cell pellet
samples. Examples of polar metabolites include sugars and most amino acids while examples of
non-polar metabolites include membrane lipids and long-chain fatty acids. We expect to observe
a greater difference in non-polar metabolites than polar metabolites since acetyl-CoA is a central
mediator of fatty acid synthesis and we hypothesize that varying levels of NAT1 activity influence
cellular metabolism through regulation of acetyl-CoA. By increasing the number of platforms used
to detect metabolites in our samples, a wider range of metabolites can be detected thus giving a
more complete picture of any metabolic flux or alterations that are occurring.
FUTURE DIRECTIONS
In the future we will be performing further metabolomics studies that cover a wider range
of metabolites, including both polar and non-polar metabolites. This will be accomplished by
applying a comprehensive metabolomics approach that will involve measurement of metabolites
across six different platforms including 1. GCXGC-TOF MS, 2. LC-MS, 3. UHPLC-MS/MS (+ESI),
4. UHPLC-MS/MS (-ESI), 5. UHPLC-MS/MS (HILIC), and 6. GC-MS (+EI). Once metabolic
differences between the cell lines are identified, we will then use biochemical approaches such as
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high pressure liquid chromatography-ultraviolet detection (HPLC-UV) and spectrophotometric
enzyme-coupled assays to verify the metabolites’ identities and then hypothesize a mechanism
by which NAT1 contributed to these differences. The biochemical approach chosen will depend
on the metabolite.
Our lab has recently completed the creation of heterozygous and homozygous NAT1
knockout MDA-MB-231 cells using the CRISPR™ system. The CRISPR™ system utilizes guide
RNA’s (gRNA’s) that specifically target one’s gene of interest, which in our case is human NAT1,
and induce DNA damage in that gene. The DNA damage and subsequent repair mechanisms
lead to mutations in the gene which result in the knockout of the gene. These two additional cell
lines with altered NAT1 activity are an incredibly valuable addition to the three transformed cell
lines used for this project. Further metabolomics studies will include two CRISPR™ homozygous
NAT1 knockout MDA-MB-231 cell lines that were constructed using two different gRNA’s. By
using MDA-MB-231 NAT1 knockouts that were generated using two different gRNA’s we will be
able to differentiate changes in metabolites that are due to NAT1 levels as opposed to possible
off target effects of the gRNA’s. We are also working on creating NAT1 knockout MCF-7 and ZR75-1 cells using the CRISPR™ system.
Also, our lab is currently in the process of using the FLP-In System™ to construct MCF-7,
MCF-10a, and ZR-75-1 transfected breast cancer cell lines that stably overexpress and
underexpress human NAT1. By repeating our study with these additional cell lines, we will be
able to show that the observed changes from our initial study are repeatable and not merely a
consequence of using MDA-MB-231 cells as the parental cell line.
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ABBREVIATIONS

Acetyl-CoA

acetyl-coenzyme a

ANOVA

analysis of variance

BRCA1

breast cancer 1, early onset

BRCA2

breast cancer 2, early onset

cDNA

complementary deoxyribonucleic acid

FRT

flippase recognition target

GC×GC−TOF MS

two dimensional gas chromatogrpahy time-of-flight mass spectrometry

gRNA

guide ribonucleic acid

HPLC

high pressure liquid chromatography

mRNA

messenger ribonucleic acid

MTBSTFA

N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide

OPLS-DA

orthogonal partial least squares- discriminant analysis

NAT1

arylamine N-acetyltransferase 1

NAT2

arylamine N-acetyltransferase 2

PABA

para-aminobenzoic acid

PCA

principle component analysis

PLS-DA

partial least squares- discriminant analysis

qRT-PCR

quantitative real time polymerase chain reaction

SEM

standard error of the mean

shRNA

short hairpin ribonucleic acid

TME

tumor microenvironment
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